Atlas Trials

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Clinical trial NCT03201965 · COMPLETED

Trial details

NCT number
NCT03201965
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Amyloidosis
Start date
2017-10-05
Primary completion
2020-02-14
Enrollment
416

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.